# Report 5: CDx Company Landscape (Updated)

## 1. Executive Summary
This report summarizes the major Companion Diagnostic (CDx) manufacturers identified in the OncoKB FDA-approved dataset.
*Update Note:* Updated to fully reflect the 8 FDA-approved indications for **Caris Life Sciences (MI Cancer Seek)**.

---

## 2. Foundation Medicine, Inc.
**Dominance:** The clear market leader for NGS-based CDx.

### Device: FoundationOne CDx (F1CDx)
*   **Pan-Cancer:** NTRK1/2/3 Fusions, MSI-High, TMB-High.
*   **NSCLC:** EGFR, ALK, MET, BRAF.
*   **Prostate:** HRR Genes (BRCA, ATM, etc).
*   **Breast:** PIK3CA, HER2.
*   **Ovarian:** BRCA1/2.
*   **Melanoma:** BRAF.

### Device: FoundationOne Liquid CDx
*   **Liquid Biopsy:** Covers subsets of NSCLC, Prostate, Breast, and Colorectal indications.

---

## 3. Caris Life Sciences
**Status:** Major NGS Player with broad FDA approvals (MI Cancer Seek).
**Key Indication count:** 8 distinct approved indications.

### Device: MI Cancer Seek (MCS)
*   **Solid Tumors (General):**
    *   **Pembrolizumab / Dostarlimab:** Microsatellite Instability-High (**MSI-H**)
*   **Colorectal Cancer:**
    *   **Cetuximab / Panitumumab:** **KRAS** Wildtype & **NRAS** Wildtype
    *   **Encorafenib + Cetuximab:** **BRAF** V600E
*   **Breast Cancer:**
    *   **Alpelisib:** **PIK3CA** Mutations
*   **Melanoma:**
    *   **Dabrafenib / Trametinib:** **BRAF** V600E/K
*   **Non-Small Cell Lung Cancer (NSCLC):**
    *   **EGFR Inhibitors:** **EGFR** Exon 19 del / L858R
*   **Endometrial Cancer:**
    *   **Lenvatinib + Pembrolizumab:** **pMMR** (Not MSI-H) status.

---

## 4. Roche Molecular Systems, Inc. / Life Technologies
**Focus:** PCR and NGS (Oncomine).

### Devices: cobas PCR Tests
*   **NSCLC:** EGFR
*   **Colorectal:** KRAS
*   **Melanoma:** BRAF
*   **Lymphoma:** EZH2

### Device: OncoKB Dx Target Test
*   **NSCLC:** BRAF, EGFR Exon 20, RET, ROS1
*   **Thyroid:** RET
*   **Glioma:** IDH1/2

---

## 5. QIAGEN
**Focus:** "therascreen" PCR kits.

### Devices: therascreen PCR Kits
*   **NSCLC:** KRAS G12C, EGFR
*   **Colorectal:** KRAS G12C, KRAS Wildtype
*   **Breast:** PIK3CA
*   **Bladder:** FGFR3

---

## 6. Myriad Genetic Laboratories, Inc.
**Focus:** Hereditary Cancer (HRD/BRCA).

### Device: BRACAnalysis CDx & myChoice CDx
*   **Ovarian, Breast, Prostate, Pancreatic:** BRCA1/2 & HRD Status.

---

## 7. Guardant Health, Inc.
**Focus:** Liquid Biopsy.

### Device: Guardant360 CDx
*   **NSCLC:** EGFR, KRAS G12C, ERBB2.
*   **Breast:** ESR1.

---

## 8. Verified FDA Approvals for Caris (Detailed Check)
The following 8 indications are now correctly attributed to **Caris MI Cancer Seek**:
1.  **CRC:** BRAF V600E (Encorafenib)
2.  **CRC:** KRAS Wildtype (Panitumumab/Cetuximab)
3.  **CRC:** NRAS Wildtype (Panitumumab/Cetuximab)
4.  **Melanoma:** BRAF V600E/K (Targeted Therapy)
5.  **NSCLC:** EGFR Exon 19/L858R (Targeted Therapy)
6.  **Breast:** PIK3CA (Alpelisib)
7.  **Solid Tumors:** MSI-H (Immunotherapy)
8.  **Endometrial:** pMMR / Not MSI-H (Lenvatinib + Pembrolizumab)
